DOP2016000096A - Nuevo compuesto para el tratamiento de hipoglicemia severa - Google Patents

Nuevo compuesto para el tratamiento de hipoglicemia severa

Info

Publication number
DOP2016000096A
DOP2016000096A DO2016000096A DO2016000096A DOP2016000096A DO P2016000096 A DOP2016000096 A DO P2016000096A DO 2016000096 A DO2016000096 A DO 2016000096A DO 2016000096 A DO2016000096 A DO 2016000096A DO P2016000096 A DOP2016000096 A DO P2016000096A
Authority
DO
Dominican Republic
Prior art keywords
lys
ser
leu
treatment
gly
Prior art date
Application number
DO2016000096A
Other languages
English (en)
Inventor
Lili Guo
Jorge Alsina-Fernandez
Robert Chadwick Cummins
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of DOP2016000096A publication Critical patent/DOP2016000096A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Removal Of Specific Substances (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención se refiere a un compuesto que comprende la secuencia de aminoácido de His-Ala-Gln-Gly-Thr-Phe-Leu-Ser-Asp-Tyr-Ser-Lys-Tyr-Leu-Asp-(Aib)-Lys-Lys-Ala-Gln-Glu-Phe-Val-Glu-Trp-Leu-Leu-Lys-Thr-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Lys-Ser-Lys-NH2 (SEC ID NO: 2) con solubilidad y estabilidades físicas y químicas mejoradas sobre el glucagón humano útil en el tratamiento de la diabetes y/o obesidad.
DO2016000096A 2013-12-18 2016-04-27 Nuevo compuesto para el tratamiento de hipoglicemia severa DOP2016000096A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361917597P 2013-12-18 2013-12-18

Publications (1)

Publication Number Publication Date
DOP2016000096A true DOP2016000096A (es) 2016-08-15

Family

ID=52278802

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2016000096A DOP2016000096A (es) 2013-12-18 2016-04-27 Nuevo compuesto para el tratamiento de hipoglicemia severa

Country Status (27)

Country Link
US (1) US9695225B2 (es)
EP (1) EP3083668A1 (es)
JP (1) JP2017509584A (es)
KR (1) KR20160075825A (es)
CN (1) CN105814076A (es)
AP (1) AP2016009242A0 (es)
AR (1) AR098614A1 (es)
AU (1) AU2014366424B2 (es)
BR (1) BR112016012067A2 (es)
CA (1) CA2928985A1 (es)
CL (1) CL2016001472A1 (es)
CR (1) CR20160226A (es)
DO (1) DOP2016000096A (es)
EA (1) EA201690914A1 (es)
EC (1) ECSP16024798A (es)
GT (1) GT201600117A (es)
HK (1) HK1224304A1 (es)
IL (1) IL245400A0 (es)
MA (1) MA39109B1 (es)
MX (1) MX2016007982A (es)
NZ (1) NZ719463A (es)
PE (1) PE20160848A1 (es)
PH (1) PH12016501182A1 (es)
SG (1) SG11201604154SA (es)
TN (1) TN2016000181A1 (es)
TW (1) TW201609127A (es)
WO (1) WO2015094875A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI622596B (zh) * 2015-10-26 2018-05-01 美國禮來大藥廠 升糖素受體促效劑
WO2019140024A1 (en) 2018-01-12 2019-07-18 Eli Lilly And Company Combination therapy
JP7212171B2 (ja) 2019-02-05 2023-01-24 イーライ リリー アンド カンパニー グルカゴン類似体アゴニストおよびその使用方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1891105E (pt) 2005-06-13 2012-06-27 Imp Innovations Ltd Análogos de oxintomodulina e seus efeitos sobre o comportamento da alimentação
ES2628063T3 (es) 2007-01-05 2017-08-01 Indiana University Research And Technology Corporation Análogos de glucagón que muestran una mayor solubilidad en tampones de pH fisiológicos
US20090098130A1 (en) * 2007-01-05 2009-04-16 Bradshaw Curt W Glucagon-like protein-1 receptor (glp-1r) agonist compounds
ES2558842T3 (es) 2008-06-17 2016-02-09 Indiana University Research And Technology Corporation Agonistas mixtos a base de GIP para el tratamiento de trastornos metabólicos y obesidad
CN102088989B (zh) * 2008-06-17 2014-11-26 印第安纳大学研究及科技有限公司 在生理pH缓冲液中具有增强的溶解性和稳定性的胰高血糖素类似物
KR20120087875A (ko) 2009-06-16 2012-08-07 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 Ｇｉｐ 수용체-활성 글루카곤 화합물
US20120148586A1 (en) * 2009-08-27 2012-06-14 Joyce Ching Tsu Chou Glucagon-like protein-1 receptor (glp-1r) agonists for treating autoimmune disorders
WO2011075393A2 (en) 2009-12-18 2011-06-23 Indiana University Research And Technology Corporation Glucagon/glp-1 receptor co-agonists
JP6050746B2 (ja) * 2010-05-13 2016-12-21 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションIndiana University Research And Technology Corporation Ｇタンパク質共役受容体活性を示すグルカゴンスーパーファミリーのペプチド
NZ612297A (en) 2010-12-22 2015-10-30 Univ Indiana Res & Tech Corp Glucagon analogs exhibiting gip receptor activity
DK2718318T3 (en) * 2011-06-10 2018-11-05 Hanmi Science Co Ltd New oxyntomodulin derivatives and pharmaceutical compositions for the treatment of obesity comprising these
US9309301B2 (en) 2011-06-22 2016-04-12 Indiana University Research And Technology Corporation Glucagon/GLP-1 receptor co-agonists
EP2729493B1 (en) * 2011-07-04 2020-06-10 IP2IPO Innovations Limited Novel compounds and their effects on feeding behaviour
JP6311708B2 (ja) * 2012-06-21 2018-04-18 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ Ｇｉｐ受容体活性を示すグルカゴンアナローグ

Also Published As

Publication number Publication date
KR20160075825A (ko) 2016-06-29
CR20160226A (es) 2016-07-12
US20160311881A1 (en) 2016-10-27
AP2016009242A0 (en) 2016-06-30
MA39109A1 (fr) 2017-09-29
JP2017509584A (ja) 2017-04-06
BR112016012067A2 (pt) 2017-09-26
HK1224304A1 (zh) 2017-08-18
WO2015094875A1 (en) 2015-06-25
NZ719463A (en) 2017-09-29
CL2016001472A1 (es) 2017-03-10
IL245400A0 (en) 2016-06-30
TN2016000181A1 (en) 2017-10-06
ECSP16024798A (es) 2017-05-31
AU2014366424B2 (en) 2017-02-16
EA201690914A1 (ru) 2016-09-30
US9695225B2 (en) 2017-07-04
EP3083668A1 (en) 2016-10-26
TW201609127A (zh) 2016-03-16
MX2016007982A (es) 2016-09-09
CN105814076A (zh) 2016-07-27
PH12016501182A1 (en) 2016-07-25
SG11201604154SA (en) 2016-07-28
CA2928985A1 (en) 2015-06-25
AU2014366424A1 (en) 2016-05-19
PE20160848A1 (es) 2016-09-10
AR098614A1 (es) 2016-06-01
MA39109B1 (fr) 2018-04-30
GT201600117A (es) 2017-07-06

Similar Documents

Publication Publication Date Title
CL2017003185A1 (es) Compuestos co-agonistas del glucagón y péptido-1 similar al glugacón (glp-1)
CY1121114T1 (el) Αγωνιστες γλυκαγονης/glp-1 για τη θεραπεια της παχυσαρκιας
AR098741A1 (es) Agonistas duales del receptor de glp-1 (péptido similar al glucagón 1) / glucagón
AR098738A1 (es) Análogos del péptido exendina-4 no acilados
AR102869A1 (es) Composiciones de insulina de rápida acción
EA201370178A1 (ru) Стабильные составы для парентеральной инъекции пептидных лекарственных средств
UY35072A (es) Derivados de exendina-4 como agonistas duales de GLP1/glucagón
UY35231A (es) Agonistas duales de GLP1/GIP o trigonales de GLP1/GIP/Glucagón
UA118558C2 (uk) Пептидна сполука
CR20120457A (es) Peptidos novedosos y métodos para su preparación y uso
CL2012003026A1 (es) Composicion farmaceutica que comprende pioglitazona y linagliptina; procedimiento de preparacion; uso en el tratamiento de la diabetes tipo 2 o la obesidad.
BR112014013780A8 (pt) transportador de seringa
UY35548A (es) Péptidos terapéuticos para el tratamiento de trastornos metabólicos.
CY1117603T1 (el) Η λιξισενατιδη ως προσθετο στη μετφορμινη στην θεραπευτικη αγωγη του διαβητη τυπου 2
CL2017002031A1 (es) Formulación en polvo nasal para el tratamiento de hipoglicemia
CL2014001060A1 (es) Compuestos derivados de aril-quinolina; proceso de obtencion; composicion farmaceutica que los comprende y uso en el tratamiento o profilaxis de la diabetes tipo 2, la aterosclerosis, cancer, entre otras enfermedades.
BR112013029256A8 (pt) combinação farmacêutica para uso no tratamento de pacientes com diabetes tipo 2
BR112017012406A2 (pt) formulação com relação fixa de insulina glargina/lixisenatida
CR20170376A (es) Tratamiento de pacientes pediátricos con diabetes mellitus de tipo 2 con lixisenatida
UY34575A (es) Composiciones y métodos para el tratamiento de diabetes y/u obesidad
DOP2016000096A (es) Nuevo compuesto para el tratamiento de hipoglicemia severa
ECSP13012603A (es) Nueva formulacion del cetp(1)
CL2016001473A1 (es) Compuesto analogo del glucogeno (glp-1) que comprende acido alfa aminobutirico para el tratamiento de hipoglicemia.
AR098615A1 (es) Péptido para el tratamiento de hipoglicemia severa
IN2013MU02576A (es)